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AbSTrACT
background The best strategy for maintaining clinical 
remission in patients with axial spondyloarthritis (axspa) 
has not been defined. C- OPTiMise compared dose 
continuation, reduction and withdrawal of the tumour 
necrosis factor inhibitor certolizumab pegol (CZP) 
following achievement of sustained remission in patients 
with early axspa.
Methods C- OPTiMise was a two- part, multicentre 
phase 3b study in adults with early active axspa 
(radiographic or non- radiographic). During the 48- week 
open- label induction period, patients received CZP 
200 mg every 2 weeks (Q2W). at Week 48, patients in 
sustained remission (ankylosing spondylitis Disease 
activity score (asDas) <1.3 at Weeks 32/36 and 48) 
were randomised to double- blind CZP 200 mg Q2W (full 
maintenance dose), CZP 200 mg every 4 weeks (Q4W; 
reduced maintenance dose) or placebo (withdrawal) for 
a further 48 weeks. The primary endpoint was remaining 
flare- free (flare: asDas ≥2.1 at two consecutive visits or 
asDas >3.5 at any time point) during the double- blind 
period.
results at Week 48, 43.9% (323/736) patients 
achieved sustained remission, of whom 313 were 
randomised to CZP full maintenance dose, CZP reduced 
maintenance dose or placebo. During Weeks 48 to 96, 
83.7% (87/104), 79.0% (83/105) and 20.2% (21/104) 
of patients receiving the full maintenance dose, reduced 
maintenance dose or placebo, respectively, were flare- 
free (p<0.001 vs placebo in both CZP groups). Responses 
in radiographic and non- radiographic axspa patients 
were comparable.
Conclusions Patients with early axspa who achieve 
sustained remission at 48 weeks can reduce their CZP 
maintenance dose; however, treatment should not be 
completely discontinued due to the high risk of flare 
following CZP withdrawal.
Trial registration number nCT02505542,  
ClinicalTrials. gov.
InTroduCTIon
Axial spondyloarthritis (axSpA) is a chronic inflam-
matory rheumatic disease that affects the spine 
and sacroiliac joints, causing pain, stiffness and 
fatigue.1–3 It usually manifests in early adulthood,4 
and encompasses patients with radiographic sacro-
iliitis (radiographic axSpA) and those without 
(non- radiographic axSpA). Symptoms cause consid-
erable impairment to patients’ physical function, 
work productivity and quality of life.5 6
Achievement of a state of low disease activity 
or remission is key to optimising health- related 
Key messages
What is already known about this subject?
 ► Tumour necrosis factor inhibitors (TNFi) 
are effective for the management of 
axial spondyloarthritis (axSpA), including 
radiographic and non- radiographic axSpA, with 
many patients able to achieve a state of low 
disease activity and remission.
 ► Previous studies exploring remission induction- 
and- maintenance strategies have shown that 
discontinuing TNFi after achieving remission 
can lead to flares in the majority of patients. 
However, few studies have assessed remission 
maintenance in a broad axSpA population, and 
none have formally tested a dose reduction 
strategy in axSpA.
What does this study add?
 ► C- OPTIMISE is the first randomised controlled 
trial to compare both TNFi dose continuation 
and dose reduction with the effects of 
treatment withdrawal in patients with axSpA 
who achieved sustained clinical remission after 
48 weeks’ open- label certolizumab pegol (CZP) 
treatment.
 ► During the randomised period of the study, 
significantly higher proportions of patients 
who continued on either a full or reduced CZP 
maintenance dose remained flare- free (83.7% 
and 79.0%, respectively) than patients who had 
CZP treatment withdrawn (20.2%).
How might this impact on clinical practice or 
future developments?
 ► CZP maintenance dose reduction is a feasible 
option for the long- term management of 
patients with axSpA in remission, preserving the 
clinical benefits of remaining on TNFi treatment, 
reducing costs and limiting patients’ long- term 
exposure to immunosuppressive therapy.
 o
n
 August 24, 2020 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-216839 on 7 M
ay 2020. Downloaded from
 
2 Landewé RBM, et al. Ann Rheum Dis 2020;0:1–9. doi:10.1136/annrheumdis-2019-216839
Spondyloarthritis
quality of life in patients with axSpA, and in many patients this 
can be reached through treatment with tumour necrosis factor 
inhibitors (TNFi). The high costs of TNFi7 and the possible 
consequences of long- term immunosuppression have raised the 
question of how remission, once achieved, should best be main-
tained. Trials in different systemic autoimmune diseases have 
explored remission induction- and- maintenance strategies.8–10 
Such strategies have not been formally tested in patients with 
axSpA, although previous studies have suggested that complete 
treatment withdrawal often leads to relapse.11 12 Therefore, a 
key question remaining for clinicians is whether to maintain or 
reduce TNFi treatment in patients in whom sustained remission 
has been induced.
The PEGylated, Fc- free TNFi certolizumab pegol (CZP) 
is an effective and well tolerated treatment across the axSpA 
spectrum.13 14 C- OPTIMISE is the first phase 3b randomised 
treatment strategy trial that evaluated TNFi dose reduction in 
patients with early axSpA in whom sustained remission had been 
induced. The study included a 48- week open- label induction 
period, followed by a 48- week randomised, double- blind main-
tenance period evaluating maintenance of remission following 
CZP dose continuation, CZP dose reduction or complete 
withdrawal.
MeTHodS
Study design
C- OPTIMISE was a two- part, phase 3b multicentre study evalu-
ating maintenance of remission in adult patients with early active 
axSpA. Patients were enrolled into the study from 108 study sites 
between 31 July 2015 and 24 March 2017.
During the induction period (baseline to Week 48) patients 
received open- label CZP 200 mg every 2 weeks (Q2W; after a 
loading dose of CZP 400 mg at Weeks 0, 2 and 4) for 48 weeks. 
Patients who achieved sustained remission in this period were 
eligible to enter the second part of the trial (maintenance period; 
Weeks 48 to 96). Sustained remission was defined as Ankylosing 
Spondylitis Disease Activity Score15 16 (ASDAS) inactive disease 
(ASDAS- ID: ASDAS <1.3) at Week 32 or 36, and at Week 48 
(with ASDAS <2.1 for Weeks 32 and 36).
The maintenance period (Weeks 48 to 96) was a randomised, 
parallel- group, double- blind, placebo- controlled 48- week 
study period, which evaluated the efficacy and safety of CZP 
in patients with sustained remission who received CZP 200 mg 
Q2W (full maintenance dose), CZP 200 mg every 4 weeks (Q4W; 
reduced maintenance dose) or placebo. Randomisation (1:1:1) 
was stratified by geographical region and presence or absence 
of radiographic sacroiliitis. The primary outcome was remaining 
flare- free during the maintenance period. Flare was defined as: 
ASDAS ≥2.1 (high disease activity) at two consecutive visits, or 
ASDAS >3.5 (very high disease activity) at any visit.
The maintenance period included an early escape arm for those 
patients who experienced a flare. Patients who escaped received 
open- label CZP 200 mg Q2W for a minimum of 12 weeks to 
assess possible return to clinical remission. Those escaping from 
the placebo arm received a loading dose of CZP 400 mg at 0, 2 
and 4 weeks into the escape arm.
Patient and public involvement
Patients were not involved in the study design or conduct. A lay 
summary reporting study outcomes will be made available on the 
study sponsor website approximately 1 year after the last patient 
assessment.
Patients
Patients eligible for inclusion were 18 to 45 years of age, had 
a documented diagnosis of axSpA (starting at age 18 or older) 
meeting the Assessment of SpondyloArthritis international 
Society (ASAS) classification criteria,17 symptom duration ≥3 
months and <5 years and active disease (defined as ASDAS 
≥2.1, Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) ≥4 and spinal pain ≥4 on a 0 to 10 numerical rating 
scale (BASDAI item 2)).
Patients were subclassified as having either radiographic 
axSpA (fulfilling the imaging criterion of the modified New 
York classification criteria18 (radiographic sacroiliitis was 
confirmed by two central readers, plus an adjudicator if neces-
sary)) or non- radiographic axSpA (fulfilling the ASAS but not 
the modified New York criteria imaging criterion). In addition, 
patients with non- radiographic axSpA had to have either a C- re-
active protein level above the upper limit of normal or evidence 
of active sacroiliitis on MRI (using ASAS/Outcome Measures 
in Rheumatology (OMERACT) definition of a positive MRI, 
confirmed by two central readers and an adjudicator if neces-
sary). All patients must have had inadequate response, contrain-
dication or intolerance to ≥2 non- steroidal anti- inflammatory 
drugs. Permitted concomitant medications included stable doses 
of certain analgesics, non- steroidal anti- inflammatory drugs and 
disease- modifying anti- rheumatic drugs (online supplementary 
table S1).
Full patient selection criteria are provided in the online supple-
mentary appendix. All patients provided informed consent to 
participate.
outcome measures
The primary outcome of the C- OPTIMISE study was the 
percentage of patients remaining flare- free during the mainte-
nance period; the main secondary outcome was time to flare. 
Additional key secondary outcomes included the percentage of 
patients achieving sustained remission at Week 48, and assess-
ment of disease activity at Week 96. Disease activity measures 
included assessment of ASDAS status (ASDAS- ID, low disease 
activity, high disease activity and very high disease activity),16 
ASDAS major improvement (MI; ASDAS reduction from base-
line of ≥2.0) and clinically important improvement (CII; ASDAS 
reduction from baseline of ≥1.1),16 ASAS response (ASAS20, 
ASAS40, ASAS5/6), ASAS partial remission,19 20 BASDAI50 
response and change from maintenance period baseline (Week 
48) in ASDAS, BASDAI,21 Bath Ankylosing Spondylitis Func-
tional Index (BASFI),22 Bath Ankylosing Spondylitis Metrology 
Index (BASMI; linear definition)23 24 and MRI outcomes, 
including sacroiliac joint Spondyloarthritis Research Consor-
tium of Canada (SIJ SPARCC) score25 and the Berlin modifica-
tion of the Ankylosing Spondylitis spine MRI score for activity 
(ASspiMRI- a).26
Additional outcomes included assessment at Week 96 of Maas-
tricht Ankylosing Spondylitis Enthesitis Score27 and tender and 
swollen joint counts (44 joints evaluation). For patients who 
experienced a flare during the maintenance period, outcomes 
at 12 weeks after escape to open- label CZP 200 mg Q2W are 
reported.
All treatment- emergent adverse events (TEAEs) were reported 
for the Safety Set (patients who received ≥1 dose CZP) up to 
70 days after the last dose of study medication. TEAEs were 
coded according to Medical Dictionary for Regulatory Activities 
(MedDRA) V.19.0.
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Figure 1 C- OPTIMISE study design (panel A) and patient disposition (panel B). AE, adverse event; axSpA, axial spondyloarthritis; CZP, certolizumab 
pegol; LD, loading dose; Q2W, every 2 weeks; Q4W, every 4 weeks. *Includes patients in the escape arm who completed week 96.
Study procedures and evaluations
Outcomes were assessed during study visits, scheduled for Weeks 
2, 4, 12, 24, 32, 36, 48, 52, 60, 72, 84 and 96. During the mainte-
nance period, ASDAS (used to define disease flare) was evaluated at 
Weeks 48, 50, 52, then every 4 weeks up to Week 96. For patients 
escaping to open- label treatment after experiencing a flare in the 
maintenance period, ASDAS components were assessed at 0, 2 and 
4 weeks into the escape arm, then every 4 weeks up to Week 96.
Statistical analysis
Assuming that 80%, 75% and 45% of CZP 200 mg Q2W, CZP 
200 mg Q4W and placebo patients, respectively, would remain 
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Table 1 Demographics and disease characteristics for patients 
enrolled in C- OPTIMISE
Induction 
period
Patients randomised into maintenance 
period
(n=313)
All axSpA
(n=736)
CZP 200 mg 
Q2W
(n=104)
CZP 200 mg 
Q4W
(n=105)
Placebo
(n=104)
baseline 
demographics
Age, years
  Mean (SD) 32.9 (7.0) 32.6 (7.2) 32.4 (6.9) 31.2 (6.6)
  Range 18–45 18–45 18–45 18–45
Male, n (%) 514 (69.8) 79 (76.0) 83 (79.0) 85 (81.7)
BMI, kg/m2, mean (SD) 25.7 (4.9) 25.1 (4.2) 25.9 (4.6) 24.7 (3.6)
Race, n (%)
  Caucasian 681 (92.5) 97 (93.3) 97 (92.4) 98 (94.2)
  Asian 38 (5.2) 5 (4.8) 6 (5.7) 5 (4.8)
  Other/mixed/missing 17 (2.3) 2 (1.9) 2 (1.9) 1 (1.0)
Geographical region, 
n (%)
  North America 33 (4.5) 3 (2.9) 3 (2.9) 4 (3.8)
  Western Europe 91 (12.4) 10 (9.6) 9 (8.6) 8 (7.7)
  Eastern Europe 537 (73.0) 82 (78.8) 83 (79.0) 82 (78.8)
  Asia 75 (10.2) 9 (8.7) 10 (9.5) 10 (9.6)
mNY positive, n (%) 407 (55.3) 56 (53.8) 56 (53.3) 56 (53.8)
Symptom duration, 
years
  Mean (SD) 3.3 (2.2) 3.8 (2.8) 3.4 (1.8) 3.1 (1.6)
  Median 3.5 3.9 3.5 3.3
Time since diagnosis, 
years
  Mean (SD) 2.2 (1.7) 2.5 (1.7) 2.0 (1.7) 2.1 (1.7)
  Median 1.6 2.7 1.3 1.3
HLA- B27 positive, n (%) 617 (83.8) 91 (87.5) 97 (92.4) 94 (90.4)
CRP >ULN, n (%) 344 (46.7) 55 (52.9) 51 (48.6) 44 (42.3)
Prior TNFi therapy, 
n (%)
32 (4.3) 4 (3.8) 6 (5.7) 7 (6.7)
History of enthesitis 
(heel), n (%)
184 (25.0) 30 (28.8) 35 (33.3) 24 (23.1)
History of EAMs, n (%)
  Uveitis 111 (15.1) 16 (15.4) 20 (19.0) 17 (16.3)
  Inflammatory bowel 
disease
17 (2.3) 2 (1.9) 3 (2.9) 1 (1.0)
  Psoriasis 45 (6.1) 8 (7.7) 2 (1.9) 7 (6.7)
Concomitant 
medication,* n (%)
  NSAIDs 618 (84.0) 85 (81.7) 92 (87.6) 85 (82.5)
  DMARDs 166 (22.6) 21 (20.2) 24 (22.9) 24 (23.3)
disease 
characteristics at 
Week 0, mean (Sd)
ASDAS 3.7 (0.8) 3.7 (0.7) 3.7 (0.8) 3.5 (0.8)
BASDAI 6.7 (1.4) 6.5 (1.4) 6.7 (1.5) 6.3 (1.3)
BASFI 5.3 (2.1) 5.2 (1.8) 5.3 (2.1) 4.8 (1.9)
BASMI 3.1 (1.5) 3.0 (1.3) 2.8 (1.4) 2.8 (1.6)
Tender joint count 2.6 (5.0) 1.6 (2.9) 2.5 (4.1) 1.9 (3.6)
Swollen joint count† 0.7 (2.1) 0.4 (1.3) 0.8 (1.7) 0.7 (1.6)
MASES 2.5 (3.0) 2.1 (2.8) 2.5 (3.1) 1.7 (2.5)
Imaging (MRI)
  SIJ SPARCC 8.0 (11.4) 8.4 (11.6) 10.9 (12.5) 9.4 (14.3)
Continued
Induction 
period
Patients randomised into maintenance 
period
(n=313)
All axSpA
(n=736)
CZP 200 mg 
Q2W
(n=104)
CZP 200 mg 
Q4W
(n=105)
Placebo
(n=104)
  ASspiMRI- a 3.1 (5.2) 3.5 (6.0) 2.9 (5.0) 3.2 (5.4)
disease 
characteristics at 
Week 48, mean (Sd)
ASDAS — 0.8 (0.2) 0.8 (0.2) 0.8 (0.2)
BASDAI — 0.4 (0.5) 0.4 (0.5) 0.5 (0.6)
BASFI — 0.4 (0.5) 0.3 (0.5) 0.5 (0.7)
BASMI — 2.1 (1.2) 1.9 (1.2) 2.2 (1.5)
Tender joint count — 0.2 (0.6) 0.1 (0.5) 0.2 (0.6)
Swollen joint count† — 0.0 (0.1) 0.0 (0.2) 0.0 (0.1)
MASES — 0.1 (0.5) 0.1 (0.4) 0.3 (1.3)
Imaging (MRI) —
  SIJ SPARCC — 1.0 (2.4) 1.1 (2.9) 0.7 (1.6)
  ASspiMRI- a — 0.7 (1.5) 0.7 (1.6) 0.5 (1.3)
*Any intake during induction period (Weeks 0 to 48) or maintenance period (Weeks 
48 to 96).
†44 joints.
ASDAS, Ankylosing Spondylitis Disease Activity Score; ASspiMRI- a, Ankylosing 
Spondylitis spine MRI score for activity; axSpA, axial spondyloarthritis; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body 
mass index; CRP, C- reactive protein; CZP, certolizumab pegol; DMARD, disease- 
modifying anti- rheumatic drug; EAMs, extra- articular manifestations; HLA- B27, 
human leucocyte antigen- B27; MASES, Maastricht Ankylosing Spondylitis Enthesitis 
Score; mNY, modified New York; NSAID, non- steroidal anti- inflammatory drug; Q2W, 
every 2 weeks; Q4W, every 4 weeks; SIJ SPARCC, sacroiliac joint Spondyloarthritis 
Research Consortium of Canada; TNFi, tumour necrosis factor inhibitor; ULN, upper 
limit of normal.
Table 1 Continued
flare- free during the 48- week maintenance period, a sample size 
of 210 patients was deemed sufficient to provide 98% power to 
detect a difference between CZP 200 mg Q2W versus placebo, 
and 94% power for CZP 200 mg Q4W versus placebo, using a 
two- sided significance level of 0.05. Based on the assumption 
that ~28% of patients would achieve sustained remission at the 
end of the induction period, 750 patients were planned for study 
enrolment.
The primary analysis was based on a logistic regression model 
which included treatment group, region and presence or absence 
of radiographic sacroiliitis as factors. ORs for each CZP dose 
versus placebo (with 95% two- sided CIs) were derived from the 
model, based on the percentage of patients who did not expe-
rience a flare. A fixed sequence testing procedure was used to 
account for testing of multiple doses: hypothesis testing at the 
0.05 level was first conducted for CZP 200 mg Q2W versus 
placebo, followed by CZP 200 mg Q4W versus placebo. The 
second test was only interpreted as statistically significant if the 
first test was significant at the 0.05 level. No statistical testing 
was planned for CZP 200 mg Q2W versus CZP 200 mg Q4W.
Non- responder imputation (NRI) was used to account for 
missing data for analysis of the primary outcome; if patients 
withdrew or had two consecutive missing ASDAS values these 
were designated as flares. The time to flare was analysed using 
the log- rank test and Kaplan- Meier methods. The percentage 
of patients achieving sustained remission is summarised using 
descriptive statistics (counts and percentages). Continuous data 
are summarised using mean and SD. In the maintenance period, 
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Figure 2 Patients free of flares during the maintenance period of C- OPTIMISE. Panel A shows the proportions of patients who did not experience 
flares following randomisation to CZP full maintenance dose (200 mg Q2W), CZP reduced maintenance dose (200 mg Q4W) or placebo. Panel B 
shows a Kaplan- Meier plot of time to flare. Missing values were imputed using non- responder imputation. Flare was defined as ASDAS ≥2.1 at two 
consecutive visits, or ASDAS >3.5 at any visit. CZP, certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks.
Figure 3 Patients with radiographic and non- radiographic axial spondyloarthritis not experiencing flares during the maintenance period of C- 
OPTIMISE. axSpA, axial spondyloarthritis; CZP, certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks.
binary variables were analysed using logistic regression (using 
NRI to impute missing values), and continuous data were anal-
ysed using a mixed model for repeated measures. For patients 
entering the escape arm, ASDAS status and ASDAS clinical 
responses (calculated from the start of escape medication) are 
reported using descriptive statistics.
Post- hoc analysis of predictors of flare was performed using a 
stepwise logistic regression model (details in online supplemen-
tary material).
Statistical analyses were performed using SAS Version 9.3.
reSulTS
Patient disposition and baseline characteristics
Of 1253 patients screened, 736 were enrolled into the induc-
tion part of C- OPTIMISE, including 407 patients with radio-
graphic axSpA and 329 with non- radiographic axSpA (figure 1). 
The mean age at study entry was 32.9 years, with an average 
symptom duration of 3.3 years (table 1). Baseline characteristics 
were comparable between radiographic and non- radiographic 
axSpA, but the former included a higher percentage of patients 
who were male, humanleucocyte antigen- B27 (HLA- B27) 
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Table 2 Efficacy outcomes at the end of the maintenance period (Week 96) of C- OPTIMISE (n=313)
Imputation
CZP 200 mg Q2W
(n=104) P vs placebo
CZP 200 mg Q4W
(n=105) P vs placebo
Placebo
(n=104)
ASDAS disease activity state, n (%)
  ID (<1.3) OC 75/87 (86.2) – 58/83 (69.9) – 14/24 (58.3)
  LD (≥1.3 and <2.1) OC 12/87 (13.8) – 19/83 (22.9) – 6/24 (25.0)
  HD (≥2.1 and ≤3.5) OC 0/87 (0) – 6/83 (7.2) – 4/24 (16.7)
  vHD (>3.5) OC 0/87 (0) – 0/83 (0) – 0/24 (0)
disease activity responses from Week 0, n (%)
ASDAS clinical improvement*
  CII NRI 86 (82.7) <0.001 79 (75.2) <0.001 22 (21.2)
  MI NRI 70 (67.3) <0.001 61 (58.1) <0.001 11 (10.6)
ASAS responder rates*
  20 NRI 89 (85.6) <0.001 82 (78.1) <0.001 24 (23.1)
  40 NRI 88 (84.6) <0.001 77 (73.3) <0.001 22 (21.2)
  5/6 NRI 73 (70.2) <0.001 66 (62.9) <0.001 13 (12.5)
  Partial remission NRI 81 (77.9) <0.001 74 (70.5) <0.001 18 (17.3)
BASDAI50a NRI 87 (83.7) <0.001 81 (77.1) <0.001 23 (22.1)
  Change from Week 48
Efficacy outcomes, LS mean±SE
  ASDAS MMRM 0.2±0.1 <0.001 0.5±0.1 <0.001 1.7±0.1
  BASDAI MMRM 0.6±0.2 <0.001 0.8±0.2 <0.001 3.0±0.2
  BASFI MMRM 0.3±0.2 <0.001 0.5±0.2 <0.001 1.9±0.2
  BASMI MMRM 0.0±0.1 0.074 −0.0±0.1 0.036 0.2±0.1
MRI outcomes, mean (SD; n)
  SIJ SPARCC score OC 0.2 (2.4; 79) 0.195 0.6 (3.8; 77) 0.432 1.1 (3.6; 24)
  ASspiMRI- a OC 0.0 (0.8; 79) 0.040 0.0 (0.8; 78) 0.074 0.4 (0.9; 24)
Additional outcomes, mean (SD; n)
  MASES OC 0.1 (0.6; 90) – 0.1 (0.6; 84) – −0.1 (0.9; 24)
  Tender joint count OC −0.1 (0.6; 90) – 0.1 (0.9; 84) – 0.0 (1.0; 24)
  Swollen joint count OC 0.0 (0.2; 90) – 0.0 (0.2; 84) – 0.0 (0.0; 24)
P values were obtained using a logistic regression model or, for MRI outcomes, an ANCOVA model, with factors for treatment group, geographical region and mNY classification 
(Week 48 baseline was included as a covariate in the ANCOVA model).
*Calculated from Week 0 baseline.
ANCOVA, analysis of covariance; ASAS, Assessment of Spondyloarthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS- ID/LD/HD/vHD, 
ASDAS- inactive disease/low disease/high disease/very high disease; ASspiMRI- a, Ankylosing Spondylitis spine MRI score for activity; BASDAI50, Bath Ankylosing Spondylitis 
Disease Activity Index 50% improvement; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CII, clinically important 
improvement; CZP, certolizumab pegol; LS, least squares; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MI, major improvement; MMRM, mixed effect model 
for repeated measures; mNY, modified New York; NRI, non- responder imputation; OC, observed case; Q2W, every 2 weeks; Q4W, every 4 weeks; SIJ SPARCC, sacroiliac joint 
Spondyloarthritis Research Consortium of Canada.
positive and with elevated C- reactive protein (CRP) levels 
(online supplementary table S2).
By Week 48, 323 patients had achieved sustained remis-
sion. Of these, 313 underwent 1:1:1 randomisation: 104 were 
randomised to CZP full maintenance dose, 105 to CZP reduced 
maintenance dose and 104 to placebo. A further 10 patients with 
sustained remission did not enter the maintenance period due to 
subject withdrawal or ineligibility. Compared with patients who 
entered the induction period, those entering the maintenance 
period were more likely to be male and HLA- B27 positive. Week 
48 disease characteristics were similar among patients entering 
the maintenance period (table 1).
efficacy
Induction period
During the 48- week induction period in which patients received 
open- label CZP 200 mg Q2W treatment, 43.9% of patients 
(323/736) achieved sustained remission according to the study 
definition. Results were similar among patients with radio-
graphic and non- radiographic axSpA: 42.8% (174/407) and 
45.3% (149/329) achieved sustained remission, respectively.
Maintenance period
During the maintenance period, 83.7% (87/104) and 79.0% of 
patients (83/105) who were randomised to the CZP full main-
tenance dose or CZP reduced maintenance dose, respectively, 
remained flare- free. Only 20.2% of patients (21/104) randomised 
to placebo remained flare- free (p<0.001 vs placebo for both 
CZP maintenance doses; figure 2A). The time to flare was signifi-
cantly different for each CZP dose versus placebo (p<0.001 vs 
placebo for both CZP treatment groups, log- rank test). In the 
placebo arm, the median time to flare following randomisa-
tion was 113 days (95% CI: 101 to 141), with the majority of 
flares occurring between 8 and 20 weeks post- randomisation 
(figure 2B). For CZP patients, no median time to flare could be 
determined within the 48- week timeframe. Among patients with 
radiographic or non- radiographic axSpA, similar percentages of 
patients did not experience flares (figure 3).
Post- hoc logistic regression analysis of predictors of flares 
in CZP (full and reduced maintenance dose groups combined) 
and placebo patients identified HLA- B27 negativity as a poten-
tial predictor of flares in patients randomised to CZP, but not 
in those randomised to placebo (online supplementary table 
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Table 3 Treatment- emergent adverse events during the C- OPTIMISE 
maintenance period (Weeks 48 to 96)
n (%), unless 
otherwise specified
CZP 200 mg 
Q2W
(n=104)
CZP 200 mg 
Q4W
(n=105)
Placebo
(n=104)
CZP exposure duration 
(days)
  Mean (SD) 306.9 (78.9) 300.5 (77.7) 171 (104.7)
  Median (range) 336.0 (14 to 346) 336.0 (44 to 350) 126.0 (14 to 345)
Total patient- years at risk 101.0 96.4 52.7
Any TEAE 60 (57.7) 64 (61.0) 56 (54.4)
  Event rate per 100 PY 177.2 140.0 237.1
Serious TEAEs 5 (4.8) 0 0
Discontinuation due to 
TEAEs
1 (1.0) 3 (2.9) 0
Drug- related TEAEs 14 (13.5) 20 (19.0) 14 (13.6)
Severe TEAEs 1 (1.0) 0 2 (1.9)
TEAEs of Interest
  Opportunistic 
infections
1 (1.0) 3 (2.9) 2 (1.9)
  Oral candidiasis 0 1 (1.0) 0
  Malignant or 
unspecified tumours*
0 0 0
  Serious cardiovascular 
events†
0 0 0
  Serious 
haematopoietic 
cytopenia
0 0 0
  Serious bleeding 
events‡
0 0 0
  Hepatic events§ 3 (2.9) 5 (4.8) 3 (2.9)
   Liver function 
analyses¶
3 (2.9) 4 (3.8) 2 (1.9)
  Hypersensitivity 
and anaphylactic 
reactions**
0 0 0
  Demyelinating 
disorders
0 0 0
Deaths 0 0 0
*Identified using SMQs ‘malignant or unspecified tumours’ and ‘malignant 
tumours’; also include incidence of ‘any malignancy’.
†Identified using study sponsor- defined search criteria based on a two- step process 
using identification via a predefined list of preferred terms in addition to manual 
review by the study physician.
‡Identified using SMQ ‘haemorrhage terms (excluding laboratory terms)’ in the 
subset of serious TEAEs.
§Identified using SMQs ‘cholestasis and jaundice of hepatic origin’, ‘hepatic failure, 
fibrosis and cirrhosis and other liver damage- related conditions’, ‘hepatitis, non- 
infectious’, ‘liver- related investigations, signs and symptoms’ and ‘liver- related 
coagulation and bleeding disturbances’.
¶Includes increased levels of alanine aminotransferase, aspartate aminotransferase, 
hepatic enzyme, blood bilirubin or transaminases.
**Includes incidence of ‘any hypersensitivity and anaphylactic reactions’, ‘any 
hypersensitivity reactions’ and ‘any anaphylactic reactions’. Safety events are 
reported for the Safety Set (n=736) according to MedDRA Version 19.0.
CZP, certolizumab pegol; MedDRA, Medical Dictionary for Regulatory Activities; PY, 
patient- years; Q2W, every 2 weeks; Q4W, every 4 weeks; SD, standard deviation; 
SMQ, standard MedDRA query; TEAE, treatment- emergent adverse event.
S3). The model did not identify any other variables as possible 
predictors of flare.
Escape arm
During the maintenance period, 95 patients who experienced 
flares (7 randomised to CZP full maintenance dose, 15 to CZP 
reduced maintenance dose and 73 to placebo) entered an open- 
label escape arm. The mean (SD) ASDAS at the time of flare for 
patients in the CZP full and reduced maintenance dose groups 
was 2.5 (1.1) and 2.3 (0.6), respectively, while in the placebo 
group ASDAS was 3.4 (1.0). Twelve weeks after treatment 
re- initiation with open- label CZP 200 mg Q2W following flare, 
clinical remission (ASDAS- ID) was regained in 63.4% (45/71), 
60.0% (9/15) and 16.7% (1/6) of patients escaping from the 
placebo, CZP reduced maintenance dose and CZP full main-
tenance dose arms, respectively. An ASDAS <2.1 (ASDAS low 
disease activity) was reached in 90.1% (64/71), 80.0% (12/15) 
and 66.7% (4/6) of patients, respectively. For other efficacy 
measures, including BASDAI, BASFI and SIJ SPARCC, disease 
activity was highest in the placebo group at the time of flare, 
but showed improvements after 12 weeks of escape treatment 
(online supplementary table S4).
other efficacy outcomes
At Week 96, a significantly higher percentage of patients 
randomised to the CZP full or reduced maintenance dose 
achieved an ASDAS clinical improvement (CII or MI), ASAS20/40 
or BASDAI50 response compared with placebo (table 2), with 
responses calculated from Week 0.
Between Weeks 48 and 96, in patients randomised to the CZP 
full or reduced maintenance dose, disease activity (ASDAS and 
BASDAI), function (BASFI) and mobility (BASMI) remained 
stable (table 2). In patients randomised to placebo, disease 
activity (ASDAS and BASDAI) and function (BASFI) worsened 
between Weeks 48 and 96 (table 2).
In all three treatment groups, there were minimal changes in 
MRI outcomes (SIJ SPARCC and ASspiMRI- a) in patients who 
remained on randomised treatment (table 2).
Safety
During the maintenance period, TEAEs were reported in 57.7%, 
61.0% and 54.4% of patients randomised to CZP 200 mg Q2W, 
CZP 200 mg Q4W or placebo, respectively (table 3). Serious 
TEAEs were reported in five patients randomised to CZP 
200 mg Q2W: these included one case each of acute pancreatitis, 
Crohn’s disease and anal abscess, which the study investigators 
did not consider to be treatment- related, and one case each 
of intestinal obstruction and latent tuberculosis, which were 
considered by the study investigators to be treatment- related. 
No serious TEAEs led to patient withdrawal from the study, and 
complete recovery was reported for all five cases. There were 
no malignancies, serious cardiovascular events or deaths during 
the study.
dISCuSSIon
C- OPTIMISE demonstrates that patients with early axSpA 
who achieve sustained remission after 48 weeks’ full dose CZP 
(200 mg Q2W) treatment can reduce their dose without further 
increasing their risk of flares in disease activity, but that they 
should not completely stop treatment. This is an important 
finding for clinicians who face decisions on how best to manage 
axSpA patients in sustained remission. These results also have 
implications for patients, who are typically in their late 20s or 
early 30s at symptom onset and who fear long- term continua-
tion of immunosuppressive therapy. Furthermore, the option to 
reduce the maintenance dose can ease the economic burden of 
TNFi treatment.
While previous studies have explored TNFi tapering or 
withdrawal in patients with axSpA following remission 
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induction,11 12 28 C- OPTIMISE is the first randomised controlled 
trial to compare both dose continuation and reduction with the 
effects of TNFi withdrawal. In keeping with the results from 
C- OPTIMISE, ABILITY-3 showed that adalimumab withdrawal 
led to significantly more flares than continuation; however, 
there was no comparison with a reduced dose arm in ABILITY-3, 
which also included only patients with non- radiographic 
axSpA.11 C- OPTIMISE recruited patients with both subforms 
of axSpA (radiographic and non- radiographic), and patients 
were on average younger (32.9 vs 37.3 years) and had shorter 
symptom duration (3.3 vs 7.7 years) compared with ABILITY-3. 
The induction period of C- OPTIMISE was also longer (48 vs 28 
weeks), although in both studies patients had to be in remission 
(ASDAS- ID) for at least 12 weeks to be eligible for randomisa-
tion. In C- OPTIMISE, more patients randomised to CZP (full 
or reduced dose) maintained remission (~80%) compared with 
ABILITY-3 (70%); however, in the withdrawal arm more patients 
in ABILITY-3 maintained remission (47%) than in C- OPTI-
MISE (20%). This difference may be attributable to differences 
in patient populations. The inclusion of both radiographic and 
non- radiographic axSpA patients in C- OPTIMISE demonstrated 
the benefits of dose reduction across the entire axSpA spectrum.
The use of ASDAS- ID (<1.3) as the definition of remis-
sion in C- OPTIMISE aligns with recommendations in current 
treat- to- target guidelines for axSpA.2 Additionally, the recently 
published ASAS- flare definition is based on ASDAS, but was not 
yet available at the time of the design of the current study.29 The 
advantages of ASDAS are the combination of patient- reported 
outcomes and an objective measure of inflammation (ie, CRP) 
as well as validated cut- offs for various levels of disease activity 
and improvement.
Approximately two- thirds of patients who experienced flares 
following complete withdrawal of CZP were able to regain 
their status of remission following 12 weeks of rescue treatment 
with open- label CZP 200 mg Q2W; similar results were seen 
for patients escaping from the reduced maintenance dose arm, 
although patient numbers in this group were smaller. A high 
proportion of escapers from the placebo arm achieved ASDAS 
<2.1 (~90%) after 12 weeks of rescue treatment, so it is possible 
that with continued treatment beyond 12 weeks more patients 
would regain their initial response (ASDAS- ID).
Identification of predictors of flare could help to optimise 
chances of successfully maintaining remission following either 
dose reduction or withdrawal. Post- hoc analyses in C- OPTI-
MISE identified HLA- B27 negativity as a possible predictor of 
flare in patients who continued on CZP treatment, but did not 
identify any predictors in placebo- randomised patients. Given 
the small number of flares in the CZP treatment groups, further 
investigation into this result is required.
No new safety concerns were identified throughout the entire 
study period. Five serious TEAEs were reported, all of which 
occurred in patients continuing on the full CZP maintenance 
dose. A full recovery was made for all five events, including the 
two serious TEAEs considered by the study investigator to be 
treatment- related. Nevertheless, this may add to the relevance of 
TNFi dose reduction in patients when clinically possible.
A potential limitation of the C- OPTIMISE study is the fact 
that enrolment was limited to patients with <5 years’ symptom 
duration, so it is unclear whether the results may be generalised 
to patients with more established disease.
In summary, in early axSpA patients in sustained remission 
after 1 year of open- label treatment with CZP, reducing the main-
tenance dose of CZP enabled patients to maintain their state of 
remission, while completely stopping treatment resulted in flares 
in the majority of patients. CZP maintenance dose reduction is 
therefore a feasible option for the long- term management of this 
chronic rheumatic disease, which has the advantage of preserving 
the clinical benefits of remaining on TNFi treatment, reducing 
costs and limiting patients’ long- term exposure to immunosup-
pressive therapy.
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